Availability and buying
where to get retatrutide
Published May 2, 2026Updated May 3, 2026Medical safety, official-source, and research-reference review
The official answer is clinical trials, not public sale. Retatrutide is not yet available for public use.
Direct answer
Lilly says retatrutide is legally available only to participants in Lilly clinical trials. It is not approved for public prescription, retail sale, or normal pharmacy access.
Research context
These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.
Short source quoteagonist of the GIP, GLP-1, and glucagon receptors
Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial
This peer-reviewed phase 2 paper is the anchor for retatrutide mechanism language. It does not make retatrutide approved or publicly available.
Short source quoterandomised, double-blind, placebo and active-controlled
Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial
The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.
Short source quotequality of the prescription drugs sold online
Lim et al., 2022 systematic review of online pharmacies selling prescription drugs
This systematic review supports online-source caution for prescription-drug searches and marketplace claims.
Short source quoteselling counterfeit, adulterated or unapproved drugs
Limbu and Huhmann, 2023 scoping review of illicit online pharmacies
This scoping review supports warnings about illicit online pharmacies and unapproved prescription-drug access.
Short source quotepreparation errors
McCall et al., Expert Opinion on Drug Safety 2026 compounded GLP-1 pharmacovigilance study
This pharmacovigilance study is relevant to compounded GLP-1 safety signals and product-quality concerns.
What to know before acting on this search
- Retatrutide is investigational and is not FDA approved for public sale or prescription.
- Lilly says retatrutide is legally available only to participants in Lilly clinical trials while safety and efficacy are evaluated.
- FDA warns that some products sold as research-use or not-for-human-consumption GLP-1 drugs may be unapproved, unknown-quality, and harmful.
- ClinicalTrials.gov can help users check public trial records and recruiting status.
Safety and compliance notes
- A website claiming stock does not prove regulatory approval or product quality.
- Import, compounding, and research-use claims can carry legal and safety problems.
- The safest practical path is to discuss approved treatments or trial eligibility with a clinician.
Safer next step
Check the clinical-trials page for legal access context and the online warning page before trusting source-page claims.
Medical disclaimer
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.